BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents  Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 13, 2020
Deals

Daily Chart: AbbVie’s deals by disease and type

In the seven years since its split from Abbott, AbbVie has entered at least 38 disclosed therapeutics deals, including 20 in cancer. Within cancer, AbbVie has engaged in about twice as many licensing and acquisition...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | Jun 10, 2020
Finance

Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects

Four years after its launch as the manager of companies in J&J’s Belgian incubator, Bioqube Ventures has raised €60 million toward its first independent venture fund earmarked for European start-ups operating in its sweet spots...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

UCB buying Engage for $125M  UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million...
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | May 1, 2020
Regulation

As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

FDA’s approval of a subcutaneous form of Darzalex secures J&J’s leading position in the anti-CD38 market just two months after a new entrant threatened to cut into its market share. It’s also a game changer...
Items per page:
1 - 10 of 1074
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents  Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019...
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 13, 2020
Deals

Daily Chart: AbbVie’s deals by disease and type

In the seven years since its split from Abbott, AbbVie has entered at least 38 disclosed therapeutics deals, including 20 in cancer. Within cancer, AbbVie has engaged in about twice as many licensing and acquisition...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | Jun 10, 2020
Finance

Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects

Four years after its launch as the manager of companies in J&J’s Belgian incubator, Bioqube Ventures has raised €60 million toward its first independent venture fund earmarked for European start-ups operating in its sweet spots...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

UCB buying Engage for $125M  UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler combo in Phase II testing for the rapid termination of epileptic seizures. Engage will receive $125 million...
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | May 1, 2020
Regulation

As first subcutaneous anti-CD38 mAb, Darzalex Faspro secures J&J’s lead in MM, shaves hours off infusion time

FDA’s approval of a subcutaneous form of Darzalex secures J&J’s leading position in the anti-CD38 market just two months after a new entrant threatened to cut into its market share. It’s also a game changer...
Items per page:
1 - 10 of 1074